Extended release pharmaceutical formulation

A method for the prevention, treatment, and/or management in a patient of a condition selected from the group consisting of depression;

• treatment-resistant depression;
• and treatment-resistant anxiety, including but not limited to DSM-V Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Post-Traumatic Stress Disorder and/or Obsessive-Compulsive Disorder, comprising:
• selecting a patient in need of the prevention, treatment, and/or management of said condition;
• administering to the patient a first dosage course comprising a dosage of about 60 mg, about 120 mg or about 180 mg of an active agent selected from the group consisting of ketamine, norketamine, and combinations thereof, administered as an oral dosage form daily for 4-7 days, and
• administering to the patient a second maintenance dosage phase comprising a dosage of about 30 mg, about 60 mg, about 120 mg, or about 180 mg of an active agent selected from the group consisting of ketamine, norketamine, and combinations thereof, administered as an oral dosage form twice weekly for at least about 4 weeks following completion of said first dosage course,
• further wherein the first dosage course and the second maintenance dosage phase prevents, treats, and/or manages said condition in said patient.